Form 4: Integra LifeSciences CEO Acquires 343K RSUs

Integra LifeSciences Holdings Corp's President and CEO, Mojdeh Poul, acquired 343,393 restricted stock units, vesting over three years.

Summary

• Mojdeh Poul, President & CEO and Director of Integra LifeSciences Holdings Corp (IART), acquired 343,393 Restricted Stock Units (RSUs) on March 11, 2026.
• These RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the grant date of March 11, 2026.
• Following this transaction, Mojdeh Poul beneficially owns a total of 445,691 derivative securities (RSUs).
• The underlying securities for these RSUs are common stock, with each RSU converting to one share.
• Delivery of the shares will occur within 30 days following the first business day that occurs immediately after the six-month period following her separation of service, functioning as deferred compensation.
• The award is subject to accelerated vesting upon termination of employment due to death or disability, or upon a qualifying termination on or within 24 months following a change in control.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as the acquisition of a substantial RSU award by the President & CEO indicates strong alignment with long-term company performance and shareholder value.

Positives

• The acquisition of a significant number of Restricted Stock Units (343,393) by the President & CEO demonstrates strong alignment of management's interests with long-term shareholder value.
• The three-year vesting schedule encourages long-term commitment and performance from the CEO.

Future Outlook

The filing details the future vesting schedule for the acquired Restricted Stock Units, which will occur in three equal annual installments on the first, second, and third anniversaries of the March 11, 2026 grant date. Shares will be delivered post-separation of service.

Industry Context

StockSavvy.ai notes that executive equity awards like Restricted Stock Units are a common practice in the life sciences industry to align executive incentives with long-term company performance and shareholder interests. This particular grant to the President & CEO is substantial, reflecting confidence or a significant component of their compensation package.

Comparison to Industry Standards

• Executive compensation packages in the life sciences sector frequently include substantial equity components, often in the form of RSUs, to incentivize long-term value creation.
• For example, similar RSU grants are observed at companies like Medtronic or Stryker, where top executives receive multi-year vesting equity awards tied to performance or continued service.
• The 343,393 RSU grant to Integra LifeSciences' CEO is a significant award, comparable in scale to grants seen at similar-sized medical technology companies, reinforcing executive commitment.

Related Party Transactions

• Acquisition of 343,393 Restricted Stock Units by President & CEO Mojdeh Poul as part of her compensation package.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with long-term shareholder value due to the equity award.

Next Steps

• First annual vesting installment of RSUs on March 11, 2027.
• Second annual vesting installment of RSUs on March 11, 2028.
• Third annual vesting installment of RSUs on March 11, 2029.
• Delivery of shares within 30 days following the first business day after the six-month period post-separation of service.

Key Dates

Recommendation

The acquisition of a significant RSU award by the CEO is a positive indicator of management's long-term commitment and alignment with shareholder interests. However, this Form 4 filing alone does not provide sufficient information on the company's broader financial performance or strategic outlook to warrant an immediate 'buy' recommendation. It reinforces a 'hold' position for existing investors, signaling stability and executive confidence, but new investment decisions would require a more comprehensive analysis of the company's financials and market position.

Keywords

Integra LifeSciences, IART, Mojdeh Poul, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Equity Award